Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data

Loncastuximab tesirine-lpyl (ADC Therapeutics) is an anti-CD19 antibody-drug conjugate which consists of anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Data from preclinical in vitro and animal studies demonstrated its selectivity and efficacy. The phase I LOTIS-1 study for relapsed, ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Furqan, Fateeha, Hamadani, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943462/
https://www.ncbi.nlm.nih.gov/pubmed/35340719
http://dx.doi.org/10.1177/20406207221087511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943462/
https://www.ncbi.nlm.nih.gov/pubmed/35340719
http://dx.doi.org/10.1177/20406207221087511

Ejemplares similares